With Chemo, Blinatumomab Boosts DFS in Pediatric B-ALL
SAN DIEGO — The addition of the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy greatly boosted 3-year disease-free survival (DFS) ...
Day: December 8, 2024
Promising Results With Epcoritamab Monotherapy in Relapsed/Refractory CLL
SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved encouraging response rates in patients with heavily-pretreated chronic lymphocytic leukemia (CLL), according to ...
Novel PTSD Treatment Improved Symptom Severity in Phase IIb Trial
An investigational therapy for post-traumatic stress disorder (PTSD) improved symptom severity as soon as one month into a 12-week, phase ...
High-Fiber Diet Linked to Improved Stem Cell Transplant, GvHD Outcomes
SAN DIEGO — Recipients of allogeneic hematopoietic cell transplantation (allo-HCT) for blood disorders who maintain diets high in fiber show ...
‘You Don’t Just Shoot an Arrow at It’: What We Heard This Week
"You don't just shoot an arrow at it ... you throw a grenade, fire a torpedo, and drown it all ...
Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia
SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts ...
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or ...
IVIG Prophylaxis in Myeloma Cuts Infections, Ups Survival
Patients with multiple myeloma who receive intravenous immunoglobulin (IVIG) prophylaxis during treatment with teclistamab have fewer infections and better overall ...
Dietary Intervention Shows Promise in Blood Cancers
SAN DIEGO -- Increased dietary fiber had a significant association with improved outcomes in blood cancers, according to studies reported ...
Hospitalization Should Not Mean Financial Ruin for Medicare Beneficiaries
Chatterjee is a physician, health policy researcher, and an assistant professor of medicine. Macneal is a statistical analyst. Patel is ...
Rilzabrutinib Shines in Phase 3 Trial of Tough-to-Treat ITP
Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated ...
Are GLP-1 Drug Holidays a Risk Worth Taking?
In part three of this three-part Instagram Live discussion, MedPage Today editor-in-chief Jeremy Faust, MD, Karl Nadolsky, DO, and Fatima ...
GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots
SAN DIEGO -- Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a ...
24-Hour Urine Testing in Multiple Myeloma: Time to Stop?
Omitting 24-hour urine testing from multiple myeloma response assessments does not compromise accurate tracking of patients' responses to treatment, a ...
